Skip to content
Screener

Integra LifeSciences IART Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Stryker logo
StrykerSYK
$0.100.0%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$00.0%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Axogen logo
AxogenAXGN
ClearPoint Neuro logo
ClearPoint NeuroCLPT
MiMedx Group logo
MiMedx GroupMDXG

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.34B+35.1%
Enterprise value$3.09B+15.4%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemJune 30, 2026December 31, 2025
Total liabilities2,520,1132,558,538
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding
Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively921923
Additional paid-in capital1,346,2651,338,386
Treasury stock, at cost; 14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively(686,918)(689,210)
Accumulated other comprehensive loss(40,197)(30,077)
Retained earnings423,306423,441

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's common stock, par value (in dollars per share)?
Integra LifeSciences (IART) reported common stock, par value (in dollars per share) of $0.01 in Q2 2026.
How has Integra LifeSciences's common stock, par value (in dollars per share) changed year-over-year?
Integra LifeSciences's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Integra LifeSciences's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Integra LifeSciences's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.

Ask your AI about Integra LifeSciences's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude